PFI-7
Based on 1 publication(s) in Google Scholar
PFI-7 is a potent and selective GID4 (Kd = 79 nM) probe that competitively antagonizes the binding of Pro/N-degron peptides to GID4 (IC50 = 0.57 µM). PFI-7 non-covalently occupies the Pro/N-degron recognition pocket of the GID4 protein, blocking the binding of endogenous substrates (such as RNA helicase) to GID4, thereby regulating the ubiquitination and proteasomal degradation of related proteins. FI-7 can also serve as an E3 ligase ligand for synthesizing PROTACs molecules. PFI-7 can be used for cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2910938-58-6
- Formula: C24H27N5O
- Molecular Weight:401.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GID4 79 nM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
0.57 μM
|
Inhibition of GID4-HaloTag binding to PGLWKS-NanoLuc in HEK293T cells assessed by NanoBRET after 4 hrs incubation.
Inhibition of GID4-HaloTag binding to PGLWKS-NanoLuc in HEK293T cells assessed by NanoBRET after 4 hrs incubation.
|
38773330 |
| HEK-293T | IC50 |
0.35 μM
|
Competition with GID4-Tracer binding to N-terminal NanoLuc-fused GID4 in HEK293T cells assessed by NanoBRET after 2 hrs equilibration.
Competition with GID4-Tracer binding to N-terminal NanoLuc-fused GID4 in HEK293T cells assessed by NanoBRET after 2 hrs equilibration.
|
38773330 |
| HEK-293T | IC50 |
0.28 μM
|
Competition with GID4-Tracer binding to C-terminal NanoLuc-fused GID4 in HEK293T cells assessed by NanoBRET after 2 hrs equilibration.
Competition with GID4-Tracer binding to C-terminal NanoLuc-fused GID4 in HEK293T cells assessed by NanoBRET after 2 hrs equilibration.
|
38773330 |
In Vitro
PFI-7 (Serial dilution; 4 h; 2 h) engages GID4 and inhibits Pro/N-degron binding with IC50 = 0.57 µM and competes with GID4-Tracer with IC50 = 0.35 µM (GID4-N) and 0.28 µM (GID4-C)[1].
PFI-7 (Up to 10 µM; 3 days) produces minimal cytotoxicity across a panel of cell lines[1].
PFI-7 (10 µM; 24 h) reduces high-confidence GID4 interactors from 77 to 13 and disrupts DDX17/DDX21/DDX50 association in doxycycline-inducible HeLa BioID2-GID4 cells[1].
PFI-7 (10 µM; 24 h) alters 60 proteins with proteasome function intact versus 15 with proteasome inhibition, increasing DHX40 and DICER1 while decreasing KIN and CHAF1A[1].
PFI-7 (10 µM) does not change GID4 or WDR26 protein levels in HeLa or RPE1 cells[2].
PFI-7 (10 µM; 1-3 d) reduces HeLa proliferation and does not further reduce growth in GID4-depleted HeLa cells[2].
PFI-7 (10 µM; 20 h) impairs wound closure in HeLa cells and does not further impair closure in GID4-depleted HeLa cells[2].
PFI-7 (10 µM; 24 h) reduces RPE1 cell velocity, though less strongly than GID4 depletion[2].
PFI-7 (10 µM; 8 h) stabilizes ARHGAP11A, but not KIFC1, in CHX-treated HeLa cells[2].
PFI-7 (10 µM) blocks GID4 co-immunoprecipitation of ARHGAP11A and KIFC1 in Flp-In T-REx HeLa cells[2].
PFI-7 (10 µM) inhibits ARHGAP11A polyubiquitination in HeLa cells[2].
PFI-7 (10 µM; 6-12 h) decreases RhoA activity after 6 and 12 h in RhoA2G-HeLa and RhoA2G-REF52 cells[2].
PFI-7 (10 µM) reduces active RhoA in HeLa cells, and ARHGAP11A knockdown restores active RhoA[2].
PFI-7 (10 µM; 0-20 h) partially rescues wound healing in ARHGAP11A-depleted HeLa cells[2].
PFI-7 (10 µM; 24 h) partially rescues the velocity defect in ARHGAP11A-depleted RPE1 cells[2].
PFI-7 binds GID4 with its indole buried in the cavity and its benzimidazole solvent-exposed, identifying the benzimidazole as a suitable linker attachment point[3].
PFI-7 (0.5-10 µM) dose-dependently reverses NEP162-mediated BRD4 degradation, consistent with competition for GID4[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:sgControl or sgGID4 KD #1 HeLa cells
-
Concentration:10 µM
-
Incubation Time:1, 2, and 3 d
-
Result:Growth rate was reduced approximately twofold compared with DMSO controls at day 3.
The proliferation defect was not further enhanced in GID4-depleted cells.
-
Cell Line:HeLa sgControl, sgGID4 KD #1, sgGID4 KD #1 + GID4, and sgGID4 KD #2 cells
-
Concentration:10 µM
-
Incubation Time:10, 20 h
-
Result:Wound area was approximately fourfold larger than in DMSO-treated sgControl cells at 20 h.
The wound healing defect was less pronounced than in sgGID4 KD #1 and #2 cells, and the phenotype was not enhanced in GID4-depleted cells.
-
Cell Line:HeLa sgControl cells
-
Concentration:10, 50 µM
-
Incubation Time:8 h
-
Result:ARHGAP11A was stabilized at 8 h, whereas KIFC1 was not stabilized.
Chemical Information
-
CAS No. 2910938-58-6
-
Molecular Weight 401.50
-
Formula C24H27N5O
-
SMILES
O=C(N[C@@H]1CC[C@H](C2=NC(C=CC=C3)=C3N2)CC1)CNCC4=CC5=C(C=CC=C5)N4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
[1]. Owens DDG, et al. A chemical probe to modulate human GID4 Pro/N-degron interactions. Nat Chem Biol. 2024 Sep;20(9):1164-1175. [Content Brief]
[3]. Li Y, et al. Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation. Nat Struct Mol Biol. 2025 Sep;32(9):1825-1837. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PFI-7
- 2910938-58-6
- PFI7
- PFI 7
- E1/E2/E3 Enzyme
- Ligands for E3 Ligase
- E1 activating enzyme
- E2 conjugating enzyme
- E3 ligating enzyme
- Ubiquitin activating enzyme
- Ubiquitin conjugating enzyme
- Ubiquitin ligase
- E3 ligase-recruiting Moiety
- ARHGAP11A
- GID4
- PROTAC
- Pro/N-degron
- RhoA
- cell migration
- cell proliferation
- substrate-binding pocket
- ubiquitination
- wound healing
- Inhibitor
- inhibitor
- inhibit